Partnership will enable and enhance standardized American-Asian protocols
Shanghai, CN and Atlanta, USA – 13th January, 2015–. Shanghai Biotechnology Corporation (SBC), a leader in Customer-oriented R&D biomarker service provider, and AKESOgen, a respected genetics, genomics and bio repository services provider, announced they will form a strategic business development alliance which will enable joint projects with pharmaceutical and biotechnology clients in the USA and Asia. The partnership will bring together AKESOgen´s proprietary know-how in sequencing, genotyping, methylation profiling, expression profiling, PCR, qPCR, copy number variation and DNA and RNA extractions, with SBC’s extensive expertise in performing comprehensive genomic and pharmacogenomic services.
“Shanghai Biotechnology Corporation’s services are very complimentary to AKESOgen’s. This partnership will allow us to jointly develop important opportunities that span the Asian and US genomics markets” said Bob Boisjoli, CEO of AKESOgen.
Dr. Huasheng Xiao, CEO of Shanghai Biotechnology Corporation commented, “AKESOgen and its team of world class experts in the field of genomics are a natural fit for SBC to enhance our service offerings and presence in the US market.”
About Shanghai Biotechnology Corporation
SBC is a leading Chinese global biotech service provider in genomic and genetic biomarker discovery and development. The core service business of SBC is to provide highly standardized development and application of genomics/genetics biomarkers for the international pharmaceutical and diagnostic industry. The company has supported thousands of R&D projects for pharma, biotech and academia since 2001. SBC has multidisciplinary teams experienced in obtaining, integrating and analyzing complex data using the most advanced technology to explore the role of genetic variation in individual responses to drugs and susceptibility to certain diseases. For more information, visit http://www.shanghaibiotech.com/
About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.
Yuhua Li, MD PhD, Shanghai Biotechnology Corporation. +86-21-51320288, ext 8219 (office), or firstname.lastname@example.org
Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or email@example.com